Hematologic Cancers

Managing Patients with Multiple Myeloma
Beth Faiman reflects on the considerations involved with managing patients who have experienced multiple myeloma relapses. Read More ›

A novel compound called CPX-351 that combines 2 older drugs (cytarabine and daunorubicin) in a new drug-delivery platform improved survival among older patients with newly diagnosed, high-risk (secondary) acute myeloid leukemia (AML). Read More ›

Noteworthy Numbers: Lymphoma

Lymphomas, cancers that begin in lymphatic cells of the immune system, can be divided into 2 main categories: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Hodgkin lymphoma is a fairly homogeneous disease characterized by the presence of Reed-Sternberg cells. Hodgkin lymphoma is far less common than NHL—approximately 8000 new Hodgkin lymphoma cases are diagnosed in the United States annually compared with over 70,000 new cases of NHL; more than 60 types of lymphoma are included in the NHL category.1 Presented below are a few facts about various forms of lymphoma.

Read More ›

The US Food and Drug Administration has approved nivolumab (Opdivo) for patients with classical Hodgkin Lymphoma that has progressed or relapsed following autologous hematopoietic stem cell transplantation and post-transplant brentuximab vedotin, according to an announcement by the agency. Notably, the intravenous drug was granted accelerated approval, and Breakthrough Therapy Designation. Read More ›

Acute Myeloid Leukemia: Understanding the Patient’s Experience
Patients with acute myeloid leukemia (AML) often feel blindsided by their diagnosis, have trouble understanding their treatment choices, and suffer symptoms that are inadequately addressed. This is a patient population with sizable, and unmet, palliative care and psychosocial needs. Read More ›

An open-label, randomized, phase 2 study evaluated the all-oral triplet combination of ixazomib (an orally administered proteasome inhibitor) plus cyclophosphamide (at 2 different doses) and low-dose dexamethasone (ICd) as a 12-month induction therapy in previously untreated, transplant-ineligible patients with multiple myeloma (MM). Read More ›

Presence of cytogenetic abnormalities (CAs) is considered to be an important prognostic factor in patients with multiple myeloma (MM), with some evidence suggesting that bortezomib-based combinations may overcome the poor prognosis associated with CAs, such as t(4;14), t(14;16), or deletion of 17p (del [17p]). Read More ›

Imatinib mesylate (IM) at 400 mg/day is the standard of care as first-line therapy in patients with newly diagnosed, chronic-phase chronic myeloid leukemia (CP-CML). Read More ›

In contrast to current recommendations to continue tyrosine kinase inhibitor therapy indefinitely, emerging evidence indicates that patients with sustained molecular responses (MRs) on imatinib therapy may achieve deep MRs and durable treatment-free remission with nilotinib in patients with chronic-phase chronic myeloid leukemia (CP-CML). Read More ›

Oral oncolytics represent 25% to 35% of the drugs in the oncology pipeline.1 They are patient friendly, allow patients to manage their treatment, and overall, have a less disruptive effect on patient's everyday lives. Read More ›

Page 4 of 10

Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: